Pacific Biosciences of California, Inc.
HealthcareNASDAQ:PACB · NASDAQ Global Select
-$0.04 today
Vol 4.97M · Avg 6.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10214.5%
avg -988.2%
ROIC
-76.3%
avg -46.5%
ROA
-69.7%
avg -35.5%
Analysis
ROA is currently the strongest return metric at -69.7% versus its period average of -35.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christian O. Henry | President, Chief Executive Officer & Director | $1.46M | — | 58 | $3.58M | 1.15% |
Mark Van Oene | Chief Operating Officer | $977,190.00 | — | 53 | $2.24M | 0.72% |
James R. Gibson | CFO & Principal Accounting Officer | $700,506.00 | — | 56 | $74,497.00 | 0.02% |
Stephen Turner | Co-Founder | $341,250.00 | — | 58 | $1.09M | 0.35% |
David Ruggiero | Global Head of Sales & Service | — | — | — | $57,116.00 | 0.02% |
Natalie Welch | Chief People Officer | — | — | — | — | — |
Brett Atkins | General Counsel & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$1.32M
Net Sentiment
$1.32M
Net selling
Most Active
Van Oene Mark
4 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $1.32M over the last 12 months. That adds up to net selling of $1.32M. Van Oene Mark was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +52.8% | +7.9% (15yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +52.8% over three years. Forward estimates point to Revenue at +7.9% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
Avanos Medical, Inc.
NYSE:AVNS
$1.17B
SI-BONE, Inc.
NASDAQ:SIBN
$683.87M
Fulgent Genetics, Inc.
NASDAQ:FLGT
$530.52M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Orthofix Medical Inc.
NASDAQ:OFIX
$376.33M
DarioHealth Corp.
NASDAQ:DRIO
$51.63M
POMDOCTOR Ltd
POM
$12.38M
Who manages PACB?
Pacific Biosciences of California, Inc. (PACB) lists 7 active executives. The top listed executive is Christian O. Henry, President, Chief Executive Officer & Director.
Are PACB insiders buying or selling?
Recent insider activity shows net buying of $22.15M.
Explore More
Continue the stock analysis
Jump to another research area for this company.